The US Food and Drug Administration has seized 33 drugs of Caraco. Commenting on the same, Vikas Dandekar of PharmAsiaNews.com said last year there was a warning letter issued to Caraco. On the list, he said, is Tramadol. “Sun Pharma’s Caraco has grown to a good extent on the back of Tr
amadol.” Also see: US FDA seizes drugs of Sun Pharma's subsidiary;stk down 16% Here is a verbatim transcript of the exclusive interview with Vikas Dandekar on CNBC-TV18. Also see the accompanying video. Q: What do you assess will be the impact for Sun Pharma? Is it just the revenues coming from Caraco from that plant or is this also going to be a little beyond the active pharmaceutical ingredients (API) supply and then tarnishing of a good name? A: That basically is a credibility issue. A company which has got an unblemished record will always be happy to sell generics and quality comes first. Though it is an intangible issue, it matters a lot when it comes to the US market. So, this particular news has been dragging for quite a long time for Caraco. Last year, there was a warning letter issued. From January this year, Caraco had started withdrawing some of the issues include oversized tablets. This is something that is definitely a little disturbing because it has led down to all the 33 products. The chief product being Tramadol. Sun Pharma’s Caraco has grown to a good extent on the back of Tramadol.
amadol.” Also see: US FDA seizes drugs of Sun Pharma's subsidiary;stk down 16% Here is a verbatim transcript of the exclusive interview with Vikas Dandekar on CNBC-TV18. Also see the accompanying video. Q: What do you assess will be the impact for Sun Pharma? Is it just the revenues coming from Caraco from that plant or is this also going to be a little beyond the active pharmaceutical ingredients (API) supply and then tarnishing of a good name? A: That basically is a credibility issue. A company which has got an unblemished record will always be happy to sell generics and quality comes first. Though it is an intangible issue, it matters a lot when it comes to the US market. So, this particular news has been dragging for quite a long time for Caraco. Last year, there was a warning letter issued. From January this year, Caraco had started withdrawing some of the issues include oversized tablets. This is something that is definitely a little disturbing because it has led down to all the 33 products. The chief product being Tramadol. Sun Pharma’s Caraco has grown to a good extent on the back of Tramadol.For further details visit at : www.moneycontrol.com/india/news/business/us-fda-seizes-33-drugscaraco/403383
No comments:
Post a Comment